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Distinctive Characteristics of Non-small Cell Lung Cancer
(NSCLC) in the Young
A Surveillance, Epidemiology, and End Results (SEER) Analysis
Janakiraman Subramanian, MD,* Daniel Morgensztern, MD,*† Boone Goodgame, MD,*
Maria Q. Baggstrom, MD,*† Feng Gao, PhD,§ Jay Piccirillo, MD,†‡
and Ramaswamy Govindan, MD*†
Background: The median age of patients with newly diagnosed
non-small cell lung cancer (NSCLC) at presentation is 71 years. We
conducted an analysis of Surveillance, Epidemiology, and End
Results data to assess whether the presentation and outcomes of
NSCLC in younger patients (age 40 years) are different from that
in older patients (age 40 years).
Methods: We obtained the demographic, clinical, and outcomes
data for all patients diagnosed with NSCLC from 1988 to 2003 in
the Surveillance, Epidemiology, and End Results registry. Patients
were grouped by age at diagnosis into younger than or equal to 40
years (younger cohort) or older than 40 years (older cohort).
Results: During the period analyzed, we identified 2775 patients
with NSCLC in the younger cohort and 236,313 patients in the older
cohort. Compared with the older group, the younger group had
greater proportion of African Americans (19.2% versus 10.9%; p 
0.0001), Asian or Pacific Islander (10.3% versus 5.9%; p 0.0001),
women (48.7% versus 41.9%; p  0.0001), and patients with stage
IV disease (57.4% versus 43.0%; p 0.0001). Adenocarcinoma was
more common in younger patients than in the older patients (57.5%
versus 45.2%; p  0.0001). Squamous cell carcinoma was less
prevalent in the younger cohort than in older cohort (12.5% versus
26.4%; p  0.0001). Five-year overall survival and cancer specific
survival were significantly better for younger patients than for older
patients across all stages.
Conclusions: There is a greater representation of African Ameri-
cans, Asians or Pacific Islanders, women, and adenocarcinoma
histology in the younger cohort of patients with NSCLC compared
with the older cohort. Despite presenting with stage IV disease more
often, the overall and cancer-specific survivals are better in younger
cohort than in the older cohort.
Key Words: NSCLC, Lung cancer, Young patients, Age less than
40, Under 40.
(J Thorac Oncol. 2010;5: 23–28)
Lung cancer is estimated to affect 215,020 persons in theyear 2008 in United States.1 It is the most commonly
diagnosed malignancy in the United States. The clinical
presentation and outcomes for lung cancer in the young have
not been described well. The majority of published data
regarding lung cancer in the young have originated from
single institutional retrospective studies with their attendant
drawbacks. These studies have almost uniformly reported a
higher incidence of adenocarcinoma and greater representa-
tion of women in younger patients with lung cancer.2–13
However, there are conflicting data on whether younger
patients with lung cancer have better or worse outcomes
compared with the older population.2–6,8,9,11–13 Lung cancer
usually affects patients in their 60s and 70s and is not
common in younger patients (age 40 years). A large pop-
ulation study is required to describe the characteristics and
outcomes of lung cancer in the younger patients.
To the best of our knowledge, only one large popula-
tion-based study has addressed the issue of lung cancer in the
young using the Metropolitan Detroit Cancer Surveillance
System (part of the Surveillance, Epidemiology, and End
Results [SEER] database).3 Since that publication more than
10 years ago, the SEER database has grown to include several
more cancer registries. Moreover, there have been significant
changes in the diagnosis and management of non-small cell
lung cancer (NSCLC). In addition, the Metropolitan Detroit
Cancer Surveillance System study included a significant pro-
portion of patients with small cell lung cancer. Therefore, we
analyzed the SEER database to identify the differences in




In this study, we analyzed the SEER Cancer Inci-
dence Public Use Database 1988 to 2003 that was submit-
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ted in November 2006 and issued in April 2007.
(http://seer.cancer.gov). Lung tumors (site codes, C34.0-
C34.9) were extracted from the SEER database for the years
1988 to 2003. The following histologic codes were desig-
nated as NSCLC: 8010, 8012, 8013, 8020, 8046, 8050–8052,
8070–8078, 8140, 8141, 8143, 8147, 8250–8255, 8260,
8310, 8430, 8480, 8481, 8490, 8560, and 8570–8575. We
excluded patients diagnosed to have small cell lung cancer
(ICD-0-3 histology code 8041–8045). In addition, patients
without pathologic diagnosis of NSCLC and American Joint
Committee on Cancer staging information were excluded.
Only patients aged 18 years or older were included. Previ-
ously published studies have variably chosen ages ranging
from 40 to 50 years to define their “younger” cohorts of
patients with lung cancer. We chose the cutoff age of 40 years
or less at presentation to define the “younger” cohort.
Statistical Analysis
Overall survival was defined as the time from diagnosis
to death from any cause, and patients alive were censored at
the time of last recording. Based on the cause of death
information provided by the SEER database, cancer-specific
survival was defined as the time from diagnosis to death from
lung cancer only, and patients who died of other causes were
censored. 2 test was used to test the statistical significance of
difference in frequencies of gender, histology, race, and stage
between the two age groups. Overall survival and cancer-
specific survival were estimated using the Kaplan-Meier
product-limit method and compared by log-rank test. Multi-
variate Cox models were also fitted to assess the differences
among age groups, while adjusting for other known risk
factors including gender, race, histologic subtypes, stage, and
treatment modalities. Statistical analyses were performed
using the standard package SAS version 9 (SAS Institute,
Cary, NC). A p value less than 0.05 was considered signifi-
cant, and all statistical tests were two sided.
RESULTS
The SEER database included 239,088 patients with
NSCLC diagnosed from 1988 to 2003 with the median age of
68 years (range, 18–105 years) at diagnosis. The younger
group (age 40 years at diagnosis) included 2775 patients
and the older group (age40 years at diagnosis) had 236,313
patients (Table 1). The median age for the younger group was
38 years (range, 18–40 years) and it was 69 years (range,
41–105 years) for the older group. The proportion of women
with NSCLC was significantly higher in the younger group
than in the older group (48.7% versus 41.9%; p  0.0001).
There were a higher proportion of African Americans in the
younger group when compared with the older patients (19.2%
versus 10.9%; p  0.0001). The proportion of Asian or
Pacific Islanders was higher in younger patients compared
with older patients (10.3% versus 5.9%; p  0.0001).
There were significant differences in the distribution of
tumor histology between the two groups. Adenocarcinoma
was the most common histology in both groups. However,
the younger group had a higher proportion of patients with
adenocarcinoma (57.5% versus 45.2%; p  0.0001) than
the older group, whereas squamous cell carcinoma was
more common in the older group (12.5% versus 26.4%;
p  0.0001). The staging distribution for the two groups
was also significantly different. The younger group had a
higher proportion of patients with stage IV disease at
presentation than the older group (57.4% versus 43.0%;
p  0.0001). Fewer patients in the younger group pre-
sented with stage I disease as compared with the older
group (11.7% versus 20.9%; p  0.0001).
Information on surgery and radiation therapy is avail-
able in the SEER database, and there was no significant
difference in the proportion of patients undergoing surgery
between the younger and older age groups (33.6% versus
32.5%; p  0.24). The proportion of patients undergoing
radiation was significantly higher in the younger patients than
older patients (60.0% versus 45.9%; p  0.00001).
The stage-wise overall and cancer-specific 5-year sur-
vival was higher for younger patients in comparison with the
older patients (Figures 1 and 2). We conducted a multivariate
analysis to control for the effect of gender, histology, race,
tumor stage, treatment modality, and year of diagnosis on
survival (Table 2). We divided the entire population studied
into subgroups with age ranges of 10 years. Patients aged 61
to 70 years were used as the reference group, because most
patients with NSCLC are diagnosed at this age range. The
results of the multivariate analysis indicated that the risk of
mortality with NSCLC increases with age and is significantly
less in the youngest group. In addition, the multivariate
analysis indicated that male gender, large cell carcinoma,
adenosquamous, undifferentiated histology, and African
TABLE 1. Description of the SEER Population of Patients





N 2775 (1.2) 236,313 (98.8)
Gender
Men 1424 (51.3) 137,270 (58.1) 0.0001
Women 1351 (48.7) 99,043 (41.9)
Race
White 1942 (70.0) 195,349 (82.7) 0.0001
African American 534 (19.2) 25,878 (10.9)
Asian or Pacific
Islander
285 (10.3) 13,880 (5.9)
Other 14 (0.5) 1206 (0.5)
Histology
Adeno 1596 (57.5) 106,773 (45.2) 0.0001
Squamous 346 (12.5) 62,487 (26.4)
Adenosquamous 51 (1.8) 3894 (1.6)
Large cell 285 (10.3) 17,956 (7.6)
Carcinoma NOS 475 (17.1) 43,986 (18.6)
Undifferentiated 22 (0.8) 1217 (0.5)
Staging
Stage I 324 (11.7) 49,377 (20.9) 0.0001
Stage II 72 (2.6) 8929 (3.8)
Stage III 786 (28.3) 76,442 (32.3)
Stage IV 1593 (57.4) 101,565 (43.0)
NOS, not otherwise specified.
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FIGURE 2. Kaplan-Meier curves comparing stage-wise cancer-specific survival between age younger than or equal to 40
years and age older than 40 years.
FIGURE 1. Kaplan-Meier curves comparing stage-wise overall survival between age younger than or equal to 40 years and
age older than 40 years.
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American race were independent negative prognostic factors
for NSCLC.
DISCUSSION
Our analysis of the SEER database confirms the previ-
ous observations that NSCLC in young patients is character-
ized by a higher proportion of women, adenocarcinoma, and
stage IV disease than the older population with NSCLC.2–13
Interestingly, there was no difference in the number of pa-
tients undergoing surgery between the two groups, although a
greater proportion of younger patients received radiation
therapy than the older patients. In the multivariate analysis,
younger age was clearly associated with reduced risk for
death due to NSCLC. The analysis also identified male
gender, African American race, adenosquamous, year of
diagnosis before 1999, and undifferentiated and large-cell
histologies to be associated with a higher risk for lung cancer
mortality. Younger patients had better stage-wise overall and
disease-specific survival than older patients with NSCLC,
and the difference in survival was statistically significant for
all stages (p  0.0001). There was no difference in the
proportion of patients undergoing surgery between the two
groups. The younger group had a higher proportion of pa-
tients undergoing radiation therapy. However, age was a
statistically significant prognostic factor after including the
treatment information to the multivariate analysis.
Our study has the usual limitations that are typically
associated with any retrospective analysis of registry-based
data involving a group of patients not treated uniformly. In
addition, we could not evaluate the influence of tobacco use,
presence or absence of comorbidities, and treatment-re-
lated toxicities because they are not captured in the SEER
database. It is likely that the comorbidities associated with
increasing age accounted for poor outcomes in the older
population.
In this study, African Americans with NSCLC had
worse survival compared with non-African American pa-
tients. Similar findings have been reported previously.14–20
The inferior survival in patients with NSCLC of African
American descent has been attributed to socioeconomic dif-
ferences rather than intrinsic biologic variation.19,20 We ob-
served a higher proportion of African Americans in the
younger age group than Caucasians in our study. This could
be due to African Americans starting to smoke tobacco at an
earlier age or there may be biologic differences that predis-
pose to develop NSCLC at a younger age. In a case-control
study, 216 patients with NSCLC and population controls
were investigated to identify whether inefficient G2-M check-
point arrest was associated with increased risk for developing
lung cancer. The association was not statistically significant
with an OR of 1.17 (95% confidence interval [CI]: 0.73–
1.88).21 When stratified by race, inefficient G2-M checkpoint
arrest was associated with increased risk for lung cancer in
African Americans (n  62) but not in Caucasians, OR 2.25
(95% CI: 0.97–5.20). The G2-M checkpoint is activated by
DNA damage and prevents cells with chromosomal aberra-
tions from going through the cell cycle. Inefficient G2-M
checkpoint arrest results in accumulation of DNA damage,
and replication of cells with DNA damage could lead to
malignant transformation. The presence of such biologic
variations in African Americans could predispose to develop
lung cancer at an earlier age.
Our study also identified a higher proportion of younger
patients with lung cancer in the Asian or Pacific Islander
ethnic population compared with the Caucasian population.
Asian Americans have a higher proportion of never smokers
with lung cancer than Caucasian or African Americans.22
Because the SEER registry does not have data on tobacco
smoking, we do not know whether there is a higher propor-
tion of never smokers in the younger Asian or Pacific Islander
TABLE 2. Multivariate Analysis of Survival in SEER







18–30 0.793 0.668–0.942 0.008
31–40 0.815 0.780–0.851 0.0001
41–50 0.847 0.831–0.864 0.0001
51–60 0.895 0.883–0.907 0.0001
61–70 1.0 0.0001
71–80 1.193 1.179–1.206 0.0001
81–90 1.462 1.439–1.486 0.0001
91 1.837 1.734–1.946 0.0001
Sex
Female 1.0 0.0001
Male 1.17 1.160–1.181 0.0001
Race
Caucasian 1.0 0.0001
Asian or Pacific Islander 0.857 0.841–0.873 0.0001
Black 1.048 1.034–1.063 0.0001
Others 1.008 0.946–1.073 0.81
Stage
I 0.25 0.246–0.255 0.0001
II 0.427 0.415–0.439 0.0001




Carcinoma NOS 1.089 1.076–1.103 0.0001
Adenosquamous 1.136 1.096–1.178 0.0001
Large cell 1.133 1.114–1.152 0.0001
Squamous 1.044 1.032–1.056 0.0001
Undifferentiated 1.146 1.081–1.215 0.0001
Radiation therapy
Yes 1.0 0.0001
No 1.194 1.183–1.205 0.0001
Surgery
Yes 1.0 0.0001
No 2.225 2.195–2.256 0.0001
Year of diagnosis
1988–1998 1.0 0.0001
1999–2003 0.875 0.867–0.883 0.0001
NOS, not otherwise specified.
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group. However, retrospective studies from the Pacific Rim
countries have reported that never smokers with lung cancer
present at an earlier age than tobacco smokers. In addition,
never smokers with lung cancer from Pacific Rim countries
have unique risk factors for lung cancer such as exposure to
cooking fumes and polymorphisms of genes involved in
xenobiotic metabolism.23,24 It is not known whether these
same risk factors play a role in the early development of lung
cancer in Asian or Pacific Islander population living in the
United States. The Asian or Pacific Islander group in the
United States is a large and diverse population, and risk
factors identified in Asians from Pacific Rim countries may
be applicable to people of similar origin living in the
United States. The reason for the higher proportion of
younger patients with lung cancer in the Asian or Pacific
Islander ethnic group may be due to multiple reasons
including cultural and biologic differences, which require
further investigation.
Patients diagnosed with NSCLC before 1999 had in-
creased hazard of death compared with patients diagnosed
between 1999 and 2003. This improvement in outcomes may
be related to advances in diagnostic imaging, the availability
of newer treatment options, such as second line chemother-
apy, and less toxic treatment regimens. In addition, we have
made progress in the arena of supportive care for cancer
patients and the management of treatment complications. The
multivariate analysis also identified large cell and adenosqua-
mous histologies to be adverse prognostic factors in keeping
with findings from previous studies on the prognostic role of
histology in patients with NSCLC.25,26
It is unclear whether patients who develop lung cancer
at an early age have intrinsic susceptibility to develop lung
cancer or have inordinate sensitivity to tobacco-related car-
cinogenesis. The proportion of smokers appears to be similar
in younger and older patients with NSCLC, although there
are only limited data on the cumulative tobacco exposure
between the two groups.2,4,9,27 Kreuzer et al.7 reported that the
number of cigarettes smoked per day was higher in younger
patients (age 45 years) than in the older ones with NSCLC.
It is conceivable that younger patients developing
NSCLC are more susceptible to tobacco-related carcinogens
than their older counterparts. It has been hypothesized that
younger patients with genetic polymorphisms of glutathione
S-transferases resulting in loss of or reduced enzymatic ac-
tivity for detoxifying reactive metabolites of tobacco smoke
procarcinogens might be at a higher risk for developing
cancer.28,29 Some of the genetic polymorphisms of glutathi-
one S-transferases such as GSTP1 AG or GG genotype,
GSTM1 null genotype, and GSTT1 null genotype are asso-
ciated with reduced or loss of enzymatic activity. In a large
case-control study, GSTP1 GG and GSTM1 null genotypes
were not associated with increased risk for lung cancer.30
However, when the analysis was restricted to patients
younger than or equal to 55 years with both GSTP1 GG and
GSTM1 null genotype, the risk for lung cancer was signifi-
cantly increased; adjusted OR 4.03 (95% CI: 1.47–11.1).
Similar findings were reported in another case-control study
on patients diagnosed with early onset lung cancer (age 50
years), and the GSTT1 null genotype was associated with
higher risk for lung cancer; OR 3.1 (95% CI: 1.1–8.4) in
heavy smoking (23 pack-years) Caucasians.29 In addition,
the combination of GSTM1 and GSTT1 null genotypes were
associated with a greater risk for lung cancer in the same
group; OR 5.0 (95% CI: 1.1–23.6).
More recently, case-control studies have specifically
examined the role of polymorphisms of genes involved in
DNA repair pathways and xenobiotic metabolism in younger
patients. Polymorphisms of 34 well-known cell cycle control
and DNA repair genes were compared between 299 patients
with lung cancer younger than 50 years and 377 age- and
gender-matched healthy controls.31 Polymorphism of the mis-
match repair gene (DNA ligase 1) LIG1 -7CT (OR 1.7;
95% CI: 1.13–2.64) and LIG3 rs 1052536 (OR 2.05; 95% CI:
1.25–3.38) were associated with increased risk for developing
lung cancer in younger patients. Polymorphisms of genes
involved in xenobiotic metabolism and the risk of lung cancer
were studied in the same population.32 The following poly-
morphisms were associated with increased risk for develop-
ing lung cancer in younger patients: heterozygote CYP1A2
(1545Ta`C) (OR 1.5; 95% CI: 1.02–2.21), CYP1A2
(-164Ca`A) (OR 1.58; CI: 1.09–2.27), and homozygous
GSTA2 (OR 1.88; 95% CI: 1.11–3.17). Further work is
required to identify other potential risk factors that may play
a more significant role in the development of lung cancer.
In summary, NSCLC in the young is characterized by
higher frequency of African American, Asian or Pacific
Islander race, female gender, and adenocarcinoma histology
than the older population with NSCLC. Patients who develop
NSCLC at a young age could have inherited risk factors,
which in combination with tobacco smoking increase their
risk for NSCLC. These patients may be more “sensitive” to
the carcinogenic effects of tobacco smoke. Further studies
are required to better understand the molecular mecha-
nisms predisposing younger patients to develop lung can-
cer and also identify potential targets to develop new
treatment modalities.
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